Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

Monday, July 18, 2016 - 09:11 in Health & Medicine

Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net